A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Gastroschisis Repair | Hepatocellular Carcinoma | Kidney Cancer | Liver Cancer | Lung Cancer | Lymphoma | Melanoma | Mesothelioma | Non-Small Cell Lung Cancer | Oral Cancer | Pharmaceuticals | Renal Cell Carcinoma | Research | Skin | Skin Cancer | Study | Urology & Nephrology | Yervoy